EP2491997B1 - A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject - Google Patents

A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject Download PDF

Info

Publication number
EP2491997B1
EP2491997B1 EP11155922.5A EP11155922A EP2491997B1 EP 2491997 B1 EP2491997 B1 EP 2491997B1 EP 11155922 A EP11155922 A EP 11155922A EP 2491997 B1 EP2491997 B1 EP 2491997B1
Authority
EP
European Patent Office
Prior art keywords
separator
gas
substance
space
housing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP11155922.5A
Other languages
German (de)
French (fr)
Other versions
EP2491997A1 (en
Inventor
Erkki Heinonen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyaire Medical Consumables LLC
Original Assignee
CareFusion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CareFusion Corp filed Critical CareFusion Corp
Priority to EP11155922.5A priority Critical patent/EP2491997B1/en
Priority to US13/403,354 priority patent/US9572952B2/en
Priority to CN201210052766.5A priority patent/CN102648999B/en
Publication of EP2491997A1 publication Critical patent/EP2491997A1/en
Application granted granted Critical
Publication of EP2491997B1 publication Critical patent/EP2491997B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/22Carbon dioxide-absorbing devices ; Other means for removing carbon dioxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/104Preparation of respiratory gases or vapours specially adapted for anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/105Filters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/12Preparation of respiratory gases or vapours by mixing different gases
    • AHUMAN NECESSITIES
    • A62LIFE-SAVING; FIRE-FIGHTING
    • A62BDEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
    • A62B19/00Cartridges with absorbing substances for respiratory apparatus
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D53/00Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/02Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography
    • B01D53/04Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
    • B01D53/0407Constructional details of adsorbing systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D53/00Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34Chemical or biological purification of waste gases
    • B01D53/46Removing components of defined structure
    • B01D53/62Carbon oxides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D53/00Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/34Chemical or biological purification of waste gases
    • B01D53/74General processes for purification of waste gases; Apparatus or devices specially adapted therefor
    • B01D53/81Solid phase processes
    • B01D53/82Solid phase processes with stationary reactants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/18Vaporising devices for anaesthetic preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20Valves specially adapted to medical respiratory devices
    • A61M16/208Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2251/00Reactants
    • B01D2251/30Alkali metal compounds
    • B01D2251/304Alkali metal compounds of sodium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2251/00Reactants
    • B01D2251/30Alkali metal compounds
    • B01D2251/306Alkali metal compounds of potassium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2251/00Reactants
    • B01D2251/60Inorganic bases or salts
    • B01D2251/604Hydroxides
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2257/00Components to be removed
    • B01D2257/50Carbon oxides
    • B01D2257/504Carbon dioxide
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2259/00Type of treatment
    • B01D2259/45Gas separation or purification devices adapted for specific applications
    • B01D2259/4533Gas separation or purification devices adapted for specific applications for medical purposes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D53/00Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols
    • B01D53/02Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography
    • B01D53/04Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases, aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
    • B01D53/0407Constructional details of adsorbing systems
    • B01D53/0415Beds in cartridges
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02CCAPTURE, STORAGE, SEQUESTRATION OR DISPOSAL OF GREENHOUSE GASES [GHG]
    • Y02C20/00Capture or disposal of greenhouse gases
    • Y02C20/40Capture or disposal of greenhouse gases of CO2

Definitions

  • This disclosure relates generally to a housing for solid, fluidal substance removing an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject.
  • Anesthesia machines are optimized for delivering anesthesia to a patient using volatile anesthetic agent liquids.
  • the anesthetic agent is vaporized and mixed into the breathing gas stream in a controlled manner to provide a gas mixture for anesthetizing the patient for a surgical operation.
  • the most common volatile anesthetic agents are halogenated hydrocarbon chains, such as halothane, enflurane, isoflurane, sevoflurane and desflurane.
  • nitrous oxide (N 2 O) can be counted in this group of volatile anesthetic agents, although the high vapor pressure of nitrous oxide causes nitrous oxide to vaporize spontaneously in the high pressure gas cylinder, where it can be directly mixed with oxygen.
  • the anesthetizing potency of nitrous oxide alone is seldom enough to anesthetize a patient and therefore another volatile agent is used to support that.
  • anesthesia machines have been developed to minimize the consumption of the gases.
  • a defined brain partial pressure for the anesthetic agent is required. This partial pressure is maintained by keeping the anesthetic agent partial pressure in the lungs adequate.
  • the lung and body partial pressures are equal, and no net exchange of the anesthetic agent occurs between the blood and the lungs.
  • continuous lung ventilation is required.
  • Anesthesia machines are designed to provide oxygen to the patient and eliminate carbon dioxide (CO2), while preserving the anesthetic gases.
  • CO2 carbon dioxide
  • a re-breathing circuit is used.
  • exhaled gas is reintroduced for inhalation.
  • carbon dioxide must be removed from the gas, which is done with a carbon dioxide absorber.
  • the gas is supplied with additional oxygen and anesthetic agents based upon the patient demand.
  • the additional gas flow added to the re-breathing circuit can be less than 0.5 L/min although the patient ventilation may be 5-10 L/min.
  • Such ventilation of the lung is carried out using a ventilator pushing inhalation gas with overpressure to patient lungs and then allowing that to flow out passively from the pressurized lungs to the breathing circuit.
  • Ventilation carries the breathing circuit oxygen to lungs for uptake to be burned in body metabolism.
  • the outcome of this is CO2 that diffuses to lungs and becomes carried out with exhalation gas.
  • the gas is guided through absorber for CO2 removal.
  • Effective CO2 removal requires close contact with the breathing gas and the removing substance.
  • the removing substance is therefore a surface of porous structure of granules that fill the cartridge.
  • the form of this granular structure guided by the flow resistance the limitation of which is one key design goals of the breathing circuit.
  • absorber optimized for minimal resistance the gas flow path through the stacked granules is short and the flow distributes to wide area. In such structure the gas flows slowly because of large surface area providing time for reaction between the gas and absorbent granules.
  • German Patent publication 702099 describes a carbon dioxide scrubber cartridge in which a plurality of horizontal separators are used to try to avoid short circuits in gals flow through the scrubber.
  • US Patent 4717549 describes an apparatus for oxygen generation in one embodiment of which vertical limiters are shown extending from a horizontal separator.
  • the present invention provides a housing including solid fluidal granules of substance for removing an undesired respiratory gas component of a respiratory gas flow as specified in the claims.
  • the invention relates to a housing according to claim 1.
  • the invention relates to an arrangement for ventilating lungs of a subject according to claim 11.
  • FIG. 2 an arrangement 10 for ventilating lungs 11 of a subject is disclosed.
  • the arrangement comprises a ventilator 12 supplying in this specific embodiment along a tube 13 breathing gas to the lungs for an inspiration and receiving breathing gas for an expiration.
  • the ventilator may be whichever well-known type e.g. drive gas based pneumatic flow-valve or mechanical piston driven.
  • the arrangement comprises a gas mixer 14 supplying a fresh gas in this specific embodiment along a fresh gas tube 15 for the subject breathing, a breathing circuit 16 connecting lungs of the subject, the ventilator 12 and the gas mixer 14.
  • the gas mixer may comprise an anesthetic agent supply (not shown in the figure) such as an anesthetic agent vaporizer providing anesthetic agent for the subject breathing.
  • the breathing circuit 16 which may be a re-breathing circuit, comprises an inspiration limb 17 providing an inspiration gas including the fresh gas for the subject breathing and an expiration limb 18 discharging an expiration gas.
  • the ventilator is controlling the breathing circuit pressure through the tube 13.
  • the breathing circuit comprises a housing 19 for a solid fluidal substance such as granules for removing an undesired respiratory gas component of a respiratory gas flow.
  • Typical solid, fluidal substance used in anesthesia is a carbon dioxide absorbing material, which may be soda-lime, a mixture of calcium hydroxide, sodium hydroxide, potassium hydroxide and water or any other substance that can extract CO2 from gas mixture e.g. molecular sieve or amines.
  • the material may chemically react with carbon dioxide or otherwise remove it from the breathing gas.
  • the housing 19 may be detachable from the breathing circuit.
  • the breathing circuit 16 also comprises directional valves 20 and 21 guiding the gas flow in the circuit on direction indicated by arrows 22.
  • the ventilator 12 increases the breathing circuit pressure by adding the gas flow from tube 13.
  • Directional valves 20 and 21 guide the gas flow through the housing 19, including the substance removing in this embodiment carbon dioxide from the breathing gas, to the inspiration limb 17 and further along a subject limb 23 to the subject's lungs 11.
  • the ventilator 12 releases gases from the breathing circuit through the tube 13.
  • the ventilator 12 may e.g. operate an expiration valve (not shown in Figure).
  • the directional valve 20 prevents the gas flow from the subject's lungs to enter the inspiration limb 17 hereby maintaining the inspiration limb free from CO2. Instead, the exhaled gas is rich of CO2 that needs to be removed before being re-circulated for the inspiration, which is done in the housing 19 including the substance removing carbon dioxide.
  • Fig. 3 presents a schematic drawing of the housing 19 comprising a space 30 receiving the solid fluidal substance 29 used in this embodiment to absorb carbon dioxide of the respiratory gas and a wall 31 surrounding a part of the space 30.
  • the housing further comprises a first separator 35 and a second separator 36, which may be operatively connected or connectable to the wall.
  • the first separator 35 such as a mesh plate allows the gas flow but prevents the substance escaping from the space through the first separator and the gas inlet 33.
  • the second separator 36 such as a mesh plate allows the gas flow but prevents the substance escaping from the space through the second separator and the gas outlet 34. It should be noted, because the gas may flow on either direction through the space 30 of the housing 19, one of the first separator and the second separator allows the respiratory gas flow to the space and the remaining one of the first separator and the second separator lets the respiratory gas flow from the space.
  • the substance 29 is thus hold on within the housing with the first and second separator allowing the gas flow through openings 37 holding the access of the absorbent granule of the substance 29 through these openings.
  • These first and second separators may be separate layers within the housing 19 as indicated on the Fig. 3 or they may form the top and bottom ends of the housing depending on the breathing system connection interface.
  • gas inlet 33 and the gas outlet 34 can be separate and, if desired, distant from the first separator and the second separator or the first separator can also be one of the gas inlet and the gas outlet and the second separator can correspondingly be one of the remaining one of the gas inlet and the gas outlet.
  • the housing further comprises a limiter 38 between the first separator 35 and the second separator 36 to limit a movement of the solid fluidal substance inside the space 30.
  • a limiter 38 between the first separator 35 and the second separator 36 to limit a movement of the solid fluidal substance inside the space 30.
  • the limiter 38 can be extended from the first separator 35 towards the space 30 and into the substance, if it is only useful. This is especially in case it is possible to turn the housing upside down.
  • the limiter 38 is closer to one of the first separator and second separator than midway between the first separator and the second separator. Also both the limiter 38 and one of the first separator 35 and the second separator 36 can constitute an integral structure.
  • the limiter can also extend from both the first and second separator towards the space 30 making sure that the housing can be assembled on both ways.
  • the limiter can be an extension of one of the first separator and the second separator and can be long enough to reach the substance 29 even after packing of the granules of the substance during transport.
  • the limiter may extend from one of the first separator and the second separator towards the space at least 2 or more specifically 2,5 times a distance which is estimated to form between one of the first separator and the second separator and an upper level 40 of the substance when compressed at the time taken into use.
  • the substance extends vertically half-way up the dimension of the limiter.
  • the compartments 39 formed by the limiter are able to limit the movement of the substance to various directions following one of the first separator and the second separator through the space.
  • the limiter can be also separate from one of the first separator and the second separator but still that may locate close enough to limit the granules of the substance from flowing through this separation when tilting.
  • the vertical dimension of the limiter 38 is advantageously limited since all walls may enhance the channeling effect. Therefore uniform volume of the granules of the substance 29 either before or after the penetrating respiratory gas enters the limiter area is beneficial to guarantee effective CO2 removal despite of the potential local channeling caused by the limiter 38.
  • the maximum angle the granules of the substance can settle determines the optimal dimensioning of the limiter including a horizontal distance of the adjacent extensions and a vertical height or depth of the limiter.
  • maximum sloping angle 42 can be up to 45 degrees as shown in Fig. 4 . Therefore the vertical height and horizontal distance of the limiter is advantageously equal. If the potential sloping angle is smaller then the horizontal distance may be longer than the vertical height. Horizontal distance smaller than vertical height does not provide any additional benefit but may instead prevent filling of the limiter space. For practical solutions of different granules the horizontal distance to vertical height may vary from 2:1 to 1:1.
  • the packaging of the substance leaves less than 10% vertical empty space below the top separator, which may be one of the first separator and the second separator depending on which one is upwards. If the height of the volume of the substance is 10 cm, the empty space may thus be 1 cm and the required vertical dimension of the limiter is then at least 2 cm or even 2,5 cm, which is also advantageous horizontal distance of the limiter compartment 39.
  • Fig. 5 which is a cross-section of the housing of Fig.3 along lines A - A, shows one embodiment of the second separator 36 having limiter 38 constituting an integral structure.
  • the limiter comprises a first set of adjacent extensions 46 forming in this specific case a continuous structure following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction.
  • the limiter shown in Fig. 5 also comprises a second set of adjacent extensions 48 which may also form in this specific embodiment a continuous structure following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction.
  • the first set of adjacent extensions and the second set of adjacent extensions are crossing forming intersecting walls that form compartments 39.
  • the first set of adjacent extensions may form an angle of 60-90 degrees, more specifically 70-90 degrees, or even more specifically 80-90 degrees with the second set of adjacent extensions.
  • Adjacent extensions of the first set can be substantially parallel with each other.
  • adjacent extensions of the second set can be substantially parallel with each other.
  • Fig. 5 could describe the first separator 35 with the limiter 38 having same construction.
  • Fig. 6 shows a cross-section of the housing of Fig. 3 along lines A - A according to another embodiment of the second separator 36 having the limiter 38.
  • the limiter comprises a set of pins 50, leaving therebetween compartments 39, following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction.
  • the dimensional calculation above applies only for the structure of Fig 5 .
  • the pins 50 must be denser than adjacent extensions having continuous structure as shown in Fig. 5 , because the granules of the substance may flow between the pins.
  • the distance between different pins can be from 5 to 15mm, more specifically from 7 to 13 mm or even more specifically 10 mm.
  • other type of compartments 39 e.g. a honeycomb would meet the requirement of Fig. 5 and 6 .
  • An advantage of the structure is that it limits the solid fluidal substance movement independently of tilting direction and thus the compartmental division may occur on both horizontal directions.
  • the embodiment of Fig. 6 could describe the first separator 35 with the limiter 38 having same construction.
  • Fig. 7 shows another embodiment of the housing close to the embodiment of Fig. 3 .
  • the limiter 38 comprises a set of nets 52 one on the other.
  • the nets are in horizontal position being substantially parallel with the second separator 36.
  • Compartments 39 are formed between the nets.
  • Distance between the nets and the closest net to the second separator 36 can be smaller than 10 mm.
  • Distance between parallel net threads can be smaller than 20 mm.
  • the nets may be interleaved to provide better grid against movement of the fluidic granules when tilting.
  • the embodiment of Fig. 7 and 8 could describe the first separator 35 having the limiter 38 with same properties.
  • the embodiment discloses the housing and arrangement where slanting of solid fluidal substance, especially CO2 removing substance, is limited in an incompletely filled housing.
  • the top of the housing has the limiter extending into the substance, which may comprise absorbent granules.
  • the limiter may extend to the top surface of the substance accommodating any empty space within the housing because of incomplete filling or stacking of the substance during transport.
  • the limiter limits flow of granules of the substance to one side of the housing and leaving empty space to the other when turning back to usage position. Instead, the limiter distributes this one empty space to a number of small compartments within the volume spaces formed by the limiter.

Description

    BACKGROUND OF THE INVENTION
  • This disclosure relates generally to a housing for solid, fluidal substance removing an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject.
  • Anesthesia machines are optimized for delivering anesthesia to a patient using volatile anesthetic agent liquids. In such systems, the anesthetic agent is vaporized and mixed into the breathing gas stream in a controlled manner to provide a gas mixture for anesthetizing the patient for a surgical operation. The most common volatile anesthetic agents are halogenated hydrocarbon chains, such as halothane, enflurane, isoflurane, sevoflurane and desflurane. Additionally, nitrous oxide (N2O) can be counted in this group of volatile anesthetic agents, although the high vapor pressure of nitrous oxide causes nitrous oxide to vaporize spontaneously in the high pressure gas cylinder, where it can be directly mixed with oxygen. The anesthetizing potency of nitrous oxide alone is seldom enough to anesthetize a patient and therefore another volatile agent is used to support that.
  • Since the volatile anesthetic agents are expensive, they are effective greenhouse gases and further harmful to the atmospheric ozone layer, anesthesia machines have been developed to minimize the consumption of the gases. To keep patient's anesthetized, a defined brain partial pressure for the anesthetic agent is required. This partial pressure is maintained by keeping the anesthetic agent partial pressure in the lungs adequate. During a steady state, the lung and body partial pressures are equal, and no net exchange of the anesthetic agent occurs between the blood and the lungs. However, to provide oxygen and eliminate carbon dioxide, continuous lung ventilation is required.
  • Anesthesia machines are designed to provide oxygen to the patient and eliminate carbon dioxide (CO2), while preserving the anesthetic gases. To meet these goals a re-breathing circuit is used. In this patient exhaled gas is reintroduced for inhalation. Before re-inhalation carbon dioxide must be removed from the gas, which is done with a carbon dioxide absorber. Before inhalation, the gas is supplied with additional oxygen and anesthetic agents based upon the patient demand. In this arrangement, the additional gas flow added to the re-breathing circuit can be less than 0.5 L/min although the patient ventilation may be 5-10 L/min. Such ventilation of the lung is carried out using a ventilator pushing inhalation gas with overpressure to patient lungs and then allowing that to flow out passively from the pressurized lungs to the breathing circuit.
  • Ventilation carries the breathing circuit oxygen to lungs for uptake to be burned in body metabolism. The outcome of this is CO2 that diffuses to lungs and becomes carried out with exhalation gas. Before re-inhalation the gas is guided through absorber for CO2 removal. Effective CO2 removal requires close contact with the breathing gas and the removing substance. To provide large contact area, the removing substance is therefore a surface of porous structure of granules that fill the cartridge. The form of this granular structure guided by the flow resistance, the limitation of which is one key design goals of the breathing circuit. In absorber optimized for minimal resistance the gas flow path through the stacked granules is short and the flow distributes to wide area. In such structure the gas flows slowly because of large surface area providing time for reaction between the gas and absorbent granules.
  • However, such optimal wide and short cartridge design involves a problem. Because the removing material is in granules, those may move in relation to each other. Packaging of the granules into the cartridge occurs in a factory, and thereafter the cartridge is transported to customer site. During this transport the granules are experiencing shaking. This compresses the granules increasing granule packaging grade and reduces the volume of the granule bed in the cartridge. Therefore when taken into use the cartridge may have some empty space on its top. Because of this reality, the gas flows through the absorber vertically, since in horizontal flow the gas (favoring the route of the least resistance to flow) would flow through this empty space without communication with the absorbent and thus allowing the CO2 flow through the absorber.
  • In the vertical gas flow this horizontal empty space is not for any harm since that does not disturb the internal flow resistance distribution within the cartridge. However, if the top surface of the granules is slanted as shown in Figure 1, flow density at the low granule level, where the empty space 1 exists, increases over the areas of high level of granules 2. On CO2 absorber language this is known as a flow channeling. A typical cartridge 3 comprises gas input 4, a gas output 5 and mesh plates 6 and 7 for preventing granules therebetween to escape from the cartridge. A demand of CO2 removal is proportional to the flow rate and the absorbent is used locally more at the volumes of high gas flow. In these areas also the absorbent volume is smaller. These result fast absorbent wear-out on these high flow volumes. When all absorbent has been consumed the CO2 penetrates through the cartridge using this flow path wherefrom the capacity has ended increasing the inspired patient gas CO2 concentration. This signs for cartridge wear out although still unused material may exists on the reduced flow volumes. Therefore slanting reduces usable cartridge CO2 removal capacity. The surface level of the granules may get slanted if inclined during unpacking and installing the cartridge having empty space after transport.
  • German Patent publication 702099 describes a carbon dioxide scrubber cartridge in which a plurality of horizontal separators are used to try to avoid short circuits in gals flow through the scrubber.
  • US Patent 4717549 describes an apparatus for oxygen generation in one embodiment of which vertical limiters are shown extending from a horizontal separator.
  • BRIEF DESCRIPTION OF THE INVENTION
  • The above-mentioned shortcomings, disadvantages and problems are addressed herein which will be understood by reading and understanding the following specification. Accordingly, the present invention provides a housing including solid fluidal granules of substance for removing an undesired respiratory gas component of a respiratory gas flow as specified in the claims.
  • In an embodiment, the invention relates to a housing according to claim 1.
  • In another embodiment, the invention relates to an arrangement for ventilating lungs of a subject according to claim 11.
  • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1 is a schematic view of prior art cartridge when returned to normal position after tilting;
    • Figure 2 illustrates an operational diagram of an arrangement for ventilating lungs of a subject:
    • Figure 3 is a schematic view of a housing for a solid fluidal substance removing an undesired respiratory gas component of a respiratory gas flow in accordance with an embodiment;
    • Figure 4 shows a behavior of the substance when the housing of Figure 3 has been returned to the formal position after tilting;
    • Figure 5 is a cross section of the housing of Figure 3 taken along lines A - A in accordance with an embodiment;
    • Figure 6 is a cross section of the housing of Figure 3 along lines A - A according to another embodiment;
    • Figure 7 is a schematic view of a housing for a solid fluidal substance removing an undesired respiratory gas component of a respiratory gas flow in accordance with another embodiment; and
    • Figure 8 is a cross section of the housing of Figure 7 taken along lines B - B.
    DETAILED DESCRIPTION OF THE INVENTION
  • Specific embodiments are explained in the following detailed description making a reference to accompanying drawings. These detailed embodiments can naturally be modified and should not limit the scope of the invention as set forth in the claims.
  • In Fig. 2 an arrangement 10 for ventilating lungs 11 of a subject is disclosed. The arrangement comprises a ventilator 12 supplying in this specific embodiment along a tube 13 breathing gas to the lungs for an inspiration and receiving breathing gas for an expiration. The ventilator may be whichever well-known type e.g. drive gas based pneumatic flow-valve or mechanical piston driven. Also the arrangement comprises a gas mixer 14 supplying a fresh gas in this specific embodiment along a fresh gas tube 15 for the subject breathing, a breathing circuit 16 connecting lungs of the subject, the ventilator 12 and the gas mixer 14. The gas mixer may comprise an anesthetic agent supply (not shown in the figure) such as an anesthetic agent vaporizer providing anesthetic agent for the subject breathing.
  • The breathing circuit 16, which may be a re-breathing circuit, comprises an inspiration limb 17 providing an inspiration gas including the fresh gas for the subject breathing and an expiration limb 18 discharging an expiration gas. The ventilator is controlling the breathing circuit pressure through the tube 13. Also the breathing circuit comprises a housing 19 for a solid fluidal substance such as granules for removing an undesired respiratory gas component of a respiratory gas flow. Typical solid, fluidal substance used in anesthesia is a carbon dioxide absorbing material, which may be soda-lime, a mixture of calcium hydroxide, sodium hydroxide, potassium hydroxide and water or any other substance that can extract CO2 from gas mixture e.g. molecular sieve or amines. The material may chemically react with carbon dioxide or otherwise remove it from the breathing gas. The housing 19 may be detachable from the breathing circuit. Typically the breathing circuit 16 also comprises directional valves 20 and 21 guiding the gas flow in the circuit on direction indicated by arrows 22. For inhalation the ventilator 12 increases the breathing circuit pressure by adding the gas flow from tube 13. Directional valves 20 and 21 guide the gas flow through the housing 19, including the substance removing in this embodiment carbon dioxide from the breathing gas, to the inspiration limb 17 and further along a subject limb 23 to the subject's lungs 11. For expiration the ventilator 12 releases gases from the breathing circuit through the tube 13. For this purpose the ventilator 12 may e.g. operate an expiration valve (not shown in Figure). This will allow the gas flow from distended subject's lungs through the subject limb 23 to the expiration limb 18 and further through the directional valve 21 to the tube 13. The directional valve 20 prevents the gas flow from the subject's lungs to enter the inspiration limb 17 hereby maintaining the inspiration limb free from CO2. Instead, the exhaled gas is rich of CO2 that needs to be removed before being re-circulated for the inspiration, which is done in the housing 19 including the substance removing carbon dioxide.
  • Fig. 3 presents a schematic drawing of the housing 19 comprising a space 30 receiving the solid fluidal substance 29 used in this embodiment to absorb carbon dioxide of the respiratory gas and a wall 31 surrounding a part of the space 30. Through the gas inlet 33 the respiratory gas is flowing to the housing and guided through the space filled with the substance 29 to the gas outlet 34 for leaving the housing and the space 30. Depending on the application the gas may flow on either direction through the space 30 of the housing 19. The housing further comprises a first separator 35 and a second separator 36, which may be operatively connected or connectable to the wall. The first separator 35 such as a mesh plate allows the gas flow but prevents the substance escaping from the space through the first separator and the gas inlet 33. The second separator 36 such as a mesh plate allows the gas flow but prevents the substance escaping from the space through the second separator and the gas outlet 34. It should be noted, because the gas may flow on either direction through the space 30 of the housing 19, one of the first separator and the second separator allows the respiratory gas flow to the space and the remaining one of the first separator and the second separator lets the respiratory gas flow from the space. The substance 29 is thus hold on within the housing with the first and second separator allowing the gas flow through openings 37 holding the access of the absorbent granule of the substance 29 through these openings. These first and second separators may be separate layers within the housing 19 as indicated on the Fig. 3 or they may form the top and bottom ends of the housing depending on the breathing system connection interface. Further the gas inlet 33 and the gas outlet 34 can be separate and, if desired, distant from the first separator and the second separator or the first separator can also be one of the gas inlet and the gas outlet and the second separator can correspondingly be one of the remaining one of the gas inlet and the gas outlet.
  • The housing further comprises a limiter 38 between the first separator 35 and the second separator 36 to limit a movement of the solid fluidal substance inside the space 30. In Fig. 3 from the top second separator 36 extends the limiter 38 towards the space 30 into the substance. Also the limiter can be extended from the first separator 35 towards the space 30 and into the substance, if it is only useful. This is especially in case it is possible to turn the housing upside down. The limiter 38 is closer to one of the first separator and second separator than midway between the first separator and the second separator. Also both the limiter 38 and one of the first separator 35 and the second separator 36 can constitute an integral structure. The limiter can also extend from both the first and second separator towards the space 30 making sure that the housing can be assembled on both ways. Thus the limiter can be an extension of one of the first separator and the second separator and can be long enough to reach the substance 29 even after packing of the granules of the substance during transport. The limiter may extend from one of the first separator and the second separator towards the space at least 2 or more specifically 2,5 times a distance which is estimated to form between one of the first separator and the second separator and an upper level 40 of the substance when compressed at the time taken into use. Advantageously even at the lowest level the substance extends vertically half-way up the dimension of the limiter. When so, sloping of the substance after resuming the housing tilting remains distributed within the individual compartments 39 conformed by the limiter as indicated in Fig 4. Thus the compartments 39 formed by the limiter are able to limit the movement of the substance to various directions following one of the first separator and the second separator through the space. The limiter can be also separate from one of the first separator and the second separator but still that may locate close enough to limit the granules of the substance from flowing through this separation when tilting.
  • The vertical dimension of the limiter 38 is advantageously limited since all walls may enhance the channeling effect. Therefore uniform volume of the granules of the substance 29 either before or after the penetrating respiratory gas enters the limiter area is beneficial to guarantee effective CO2 removal despite of the potential local channeling caused by the limiter 38.
  • The maximum angle the granules of the substance can settle determines the optimal dimensioning of the limiter including a horizontal distance of the adjacent extensions and a vertical height or depth of the limiter. Depending on the granules of the substance, maximum sloping angle 42 can be up to 45 degrees as shown in Fig. 4. Therefore the vertical height and horizontal distance of the limiter is advantageously equal. If the potential sloping angle is smaller then the horizontal distance may be longer than the vertical height. Horizontal distance smaller than vertical height does not provide any additional benefit but may instead prevent filling of the limiter space. For practical solutions of different granules the horizontal distance to vertical height may vary from 2:1 to 1:1. Typically the packaging of the substance leaves less than 10% vertical empty space below the top separator, which may be one of the first separator and the second separator depending on which one is upwards. If the height of the volume of the substance is 10 cm, the empty space may thus be 1 cm and the required vertical dimension of the limiter is then at least 2 cm or even 2,5 cm, which is also advantageous horizontal distance of the limiter compartment 39.
  • Fig. 5, which is a cross-section of the housing of Fig.3 along lines A - A, shows one embodiment of the second separator 36 having limiter 38 constituting an integral structure. The limiter comprises a first set of adjacent extensions 46 forming in this specific case a continuous structure following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction. The limiter shown in Fig. 5 also comprises a second set of adjacent extensions 48 which may also form in this specific embodiment a continuous structure following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction. The first set of adjacent extensions and the second set of adjacent extensions are crossing forming intersecting walls that form compartments 39. The first set of adjacent extensions may form an angle of 60-90 degrees, more specifically 70-90 degrees, or even more specifically 80-90 degrees with the second set of adjacent extensions. Adjacent extensions of the first set can be substantially parallel with each other. Also adjacent extensions of the second set can be substantially parallel with each other. As well the embodiment of Fig. 5 could describe the first separator 35 with the limiter 38 having same construction.
  • Fig. 6 shows a cross-section of the housing of Fig. 3 along lines A - A according to another embodiment of the second separator 36 having the limiter 38. The limiter comprises a set of pins 50, leaving therebetween compartments 39, following the second separator 36 through the space 30 when the housing is in the upright position and the second separator is substantially in the horizontal position and in which case the respiratory gas flow through the space happens in substantial vertical direction. The dimensional calculation above applies only for the structure of Fig 5. The pins 50 must be denser than adjacent extensions having continuous structure as shown in Fig. 5, because the granules of the substance may flow between the pins. Thus the distance between different pins can be from 5 to 15mm, more specifically from 7 to 13 mm or even more specifically 10 mm. Also other type of compartments 39, e.g. a honeycomb would meet the requirement of Fig. 5 and 6. An advantage of the structure is that it limits the solid fluidal substance movement independently of tilting direction and thus the compartmental division may occur on both horizontal directions. As well the embodiment of Fig. 6 could describe the first separator 35 with the limiter 38 having same construction.
  • Fig. 7 shows another embodiment of the housing close to the embodiment of Fig. 3. The limiter 38 comprises a set of nets 52 one on the other. The nets are in horizontal position being substantially parallel with the second separator 36. Compartments 39 are formed between the nets. Distance between the nets and the closest net to the second separator 36 can be smaller than 10 mm. Distance between parallel net threads can be smaller than 20 mm. The nets may be interleaved to provide better grid against movement of the fluidic granules when tilting. As well the embodiment of Fig. 7 and 8 could describe the first separator 35 having the limiter 38 with same properties.
  • As hereinabove explained the embodiment discloses the housing and arrangement where slanting of solid fluidal substance, especially CO2 removing substance, is limited in an incompletely filled housing. For this purpose the top of the housing has the limiter extending into the substance, which may comprise absorbent granules. The limiter may extend to the top surface of the substance accommodating any empty space within the housing because of incomplete filling or stacking of the substance during transport. When tilting the housing the limiter limits flow of granules of the substance to one side of the housing and leaving empty space to the other when turning back to usage position. Instead, the limiter distributes this one empty space to a number of small compartments within the volume spaces formed by the limiter. As a result of this the height differences of the surface low's and high's is reduced when the empty space of the housing remains more evenly distributed at the top of the housing as shown in Fig. 4. This maintains even flow distribution throughout the space filled with the substance reducing the channeling and thus improving the usage of the substance, especially CO2 removal capacity.
  • The written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to make and use the invention. The patentable scope of the invention is defined by the claims.

Claims (11)

  1. A housing (19) for solid, fluidal substance removing an undesired respiratory gas component of a vertical respiratory gas flow comprising:
    a space (30) for receiving said substance;
    a vertical wall (31) surrounding part of said space;
    a first horizontal separator (35) surrounding a top part of said space allowing the gas flow but preventing said substance escaping from said space through said first separator; and
    a second horizontal separator (36) surrounding a bottom part of said space allowing gas flow but preventing said substance escaping from said space through said second separator;
    wherein one of said first separator and said second separator is adapted to allow the respiratory gas flow to said space and the remaining one of said first separator and said second separator is adapted to let the respiratory gas flow from said space, said housing further comprising
    a limiter (38) in form of a first set of adjacent extensions extending from said first horizontal separator into the substance,
    the horizontal distance between adjacent extensions and the vertical height of the extensions being equal
  2. The housing according to claim 1, characterized in that said limiter (38) and said first separator (35) is adapted to constitute an integral structure.
  3. The housing according to claim 1, characterized in that said limiter is adapted to form compartments (39) to limit the movement of the substance to various directions following one of said first separator and said second separator through said space.
  4. The housing according to claim 1, characterized in that said limiter is adapted to form a continuous structure following one of said first separator and said second separator through said space.
  5. The housing according to claim 1, characterized in that said first set of_adjacent extensions are substantially parallel.
  6. The housing according to claim 7, characterized in that said limiter also comprises a second set of adjacent extensions (48) crossing with said first set of extensions.
  7. The housing according to claim 6, characterized in that said first set of extensions are adapted to form an angle of 60-90 degrees, more specifically 70-90 degrees, or even more specifically 80-90 degrees, with said second set of adjacent_extensions.
  8. The housing according to claim 1, characterized in that said limiter comprises a set of pins (50) arranged side by side.
  9. The housing according to claim 1, characterized in that said limiter comprises a set of nets (52) one on the other.
  10. The housing according to claim 1, characterized in that said substance is a chemical compound removing carbon dioxide.
  11. An arrangement for ventilating lungs of a subject comprising:
    a ventilator (12) for supplying a breathing gas for an inspiration and for receiving a breathing gas for an expiration; and
    a gas mixer (14) for supplying a fresh gas for the subject breathing;
    a breathing circuit (16) for connecting lungs (11) of the subject, said ventilator and said gas mixer, said breathing circuit comprising an inspiration limb (17) providing an inspiration gas including the fresh gas for the subject breathing; an expiration limb (18) to discharge an expiration gas; and a housing (19) according to any of the preceding claims
EP11155922.5A 2011-02-25 2011-02-25 A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject Not-in-force EP2491997B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP11155922.5A EP2491997B1 (en) 2011-02-25 2011-02-25 A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject
US13/403,354 US9572952B2 (en) 2011-02-25 2012-02-23 Housing for solid, fluidal substance for removing an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject
CN201210052766.5A CN102648999B (en) 2011-02-25 2012-02-24 A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component and an arrangement for ventilating lungs of a subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11155922.5A EP2491997B1 (en) 2011-02-25 2011-02-25 A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject

Publications (2)

Publication Number Publication Date
EP2491997A1 EP2491997A1 (en) 2012-08-29
EP2491997B1 true EP2491997B1 (en) 2017-05-10

Family

ID=44262938

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11155922.5A Not-in-force EP2491997B1 (en) 2011-02-25 2011-02-25 A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject

Country Status (3)

Country Link
US (1) US9572952B2 (en)
EP (1) EP2491997B1 (en)
CN (1) CN102648999B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI626062B (en) * 2017-03-10 2018-06-11 新利虹科技股份有限公司 Operation method of breathing apparatus
CN115400315B (en) * 2022-09-22 2024-04-02 广东骏丰频谱股份有限公司 Filtering water tank

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717549A (en) * 1983-04-12 1988-01-05 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Oxygen chemical generation respiration apparatus

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1843446A (en) * 1926-02-19 1932-02-02 Elfriede Drager Cartridge for independent breathing apparatus
DE702099C (en) * 1938-03-25 1941-01-30 Draegerwerk Heinr U Bernh Drae Air purification cartridge
US3403981A (en) * 1964-09-22 1968-10-01 Auergesellschaft Gmbh Oxygen producing canister
US3566867A (en) * 1967-11-17 1971-03-02 Dryden Corp Unitary disposable circle absorption canister assembly
US3721238A (en) * 1970-10-29 1973-03-20 Ross W Inc Disposable anesthesia device
SE362201B (en) * 1971-02-15 1973-12-03 Aga Ab
US3942524A (en) * 1974-11-08 1976-03-09 The United States Of America As Represented By The Secretary Of The Interior Emergency breather apparatus
AU703747B2 (en) * 1994-11-15 1999-04-01 W.L. Gore & Associates, Inc. Gas adsorbent rebreather canister
SE503933C2 (en) 1995-10-04 1996-09-30 Siemens Elema Ab Device for fixing and sealing a container against, respectively. detach the container from a lid
US6667017B2 (en) * 1999-10-15 2003-12-23 Abb Lummus Global, Inc. Process for removing environmentally harmful compounds
US6619289B1 (en) * 2001-02-09 2003-09-16 Datex-Ohmeda, Inc. Carbon dioxide absorber canister with breathing gas moisture sump
AU2002253451B1 (en) * 2002-04-16 2003-10-27 African Oxygen Limited Chemical bed design
US7089933B2 (en) * 2002-10-25 2006-08-15 Hamilton Sundstrand CO2 sorbent for inhalation drug therapy system
DE102004020133B3 (en) 2004-04-24 2005-08-11 Dräger Medical AG & Co. KGaA Device used as a breathing system comprises an absorber, centering notches arranged on the front side of a guide plate, and a centering pin fixed on the absorber holder
GB0425782D0 (en) * 2004-11-24 2004-12-22 Intersurgical Ltd Improvements relating to respiratory circuits
US7424889B2 (en) 2005-04-13 2008-09-16 The General Electric Company Carbon dioxide absorber canister attachment
US7563301B2 (en) * 2006-11-21 2009-07-21 Fipak Research And Development Company Air filter with partial-depth, open-cell stabilizer to reduce detrimental shifting and settling of granular filter materials within the filter

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717549A (en) * 1983-04-12 1988-01-05 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Oxygen chemical generation respiration apparatus

Also Published As

Publication number Publication date
US20130074837A1 (en) 2013-03-28
US9572952B2 (en) 2017-02-21
CN102648999A (en) 2012-08-29
EP2491997A1 (en) 2012-08-29
CN102648999B (en) 2017-04-12

Similar Documents

Publication Publication Date Title
US5044361A (en) Method and apparatus for reuse of anesthetics
CA2103074A1 (en) Single patient use disposable carbon dioxide absorber
US10960160B2 (en) Anesthetic circuit having a hollow fiber membrane
EP2491997B1 (en) A housing for a solid or fluidal substance for the removal of an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject
US20110197889A1 (en) Arrangement and method for supplying breathing gas for respiration
CA2990545A1 (en) Oxygen rebreathing apparatus and method for using the same
EP1740878B1 (en) Vessel comprising two compartments and connection, one compartment is defilled and the other is filled
US20160045703A1 (en) Arrangement for guiding expired respiratory gas flow
Higuchi et al. The carbon dioxide absorption capacity of Amsorb® is half that of soda lime
US8992672B2 (en) Housing and housing assembly for substance removing an undesired respiratory gas component of a respiratory gas flow and an arrangement for ventilating lungs of a subject
EP2780067B1 (en) Anaesthetic re-breather circuit
EP2201979A1 (en) Arrangement and method for supplying breathing gas for respiration
US20220193467A1 (en) Adsorption filter structure or purification module and helmet comprising the same
EP2586482B1 (en) Housing assembly for substance removing an undesired respiratory gas component of a respiratory gas flow and arrangement for ventilating lungs of a subject
CN102160907A (en) Device and method for supplying breathing air to breathe
KR100770584B1 (en) System for absorbing carbon dioxide gas used in anesthesia apparatus
CN114828925A (en) Medical ventilation system
JP2009034442A (en) Oxygen inhaling apparatus for high altitudes, and carbon dioxide adsorbent agent revitalization mechanism
GB2512401A (en) Arrangement and method for guiding expired respiratory gas flow through a housing assembly for removing undesirable respiratory gas component and breathing
WO1992005826A1 (en) Anaesthetic and/or ventilator system and method to purify the gas in such a system
RU2477152C2 (en) Respiratory apparatus and respiratory apparatus operating procedure
CN211534989U (en) Mouse inhalation anesthesia device
SE537166C2 (en) Systems for the management of nitrous oxide collected from exhaled air
RU2005120059A (en) INSULATING RESPIRATORY APPARATUS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17P Request for examination filed

Effective date: 20130226

17Q First examination report despatched

Effective date: 20130412

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CAREFUSION CORPORATION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161207

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 891706

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170515

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011037720

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170510

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 891706

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170810

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170910

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170810

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602011037720

Country of ref document: DE

Owner name: VYAIRE MEDICAL CONSUMABLES LLC, METTAWA, US

Free format text: FORMER OWNER: CAREFUSION CORP., SAN DIEGO, CALIF., US

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: VYAIRE MEDICAL CONSUMABLES LLC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011037720

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180213

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20180122

Year of fee payment: 8

Ref country code: GB

Payment date: 20180122

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180225

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011037720

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190225

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180225

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170510

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230525